News Daily News FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients Yael L. Maxwell August 18, 2016
News Daily News Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients Todd Neale August 01, 2016
News Daily News Survival Benefit of CoreValve in High-Risk Patients Persists at 2 Years July 07, 2015
News Daily News Even With More Experience, Transapical TAVR Offers No Better QoL Than Surgery Caitlin E. Cox June 15, 2015